Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
about
Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysisThe E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammationMolecular biology of lung cancer: clinical implicationsMethylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesionsDNA methylation-based biomarkers for early detection of non-small cell lung cancer: an updateVILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival.Cystatin E/M suppresses legumain activity and invasion of human melanomaToll-like receptor-mediated down-regulation of the deubiquitinase cylindromatosis (CYLD) protects macrophages from necroptosis in wild-derived miceLung cancer: a modified epigenome.Time-series clustering of gene expression in irradiated and bystander fibroblasts: an application of FBPA clustering.Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas.Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer.Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia.TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancerUpdate of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signalingIntegrating the multiple dimensions of genomic and epigenomic landscapes of cancer.Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention.Evolving concepts in lung carcinogenesisHigh-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.The significance of epigenetic alterations in lung carcinogenesis.Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression.Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells.Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expressionInvasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.Histone deacetylase inhibitors facilitate partner preference formation in female prairie voles.Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturationThe impact of genomics in understanding human melanoma progression and metastasis.Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells.Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.CYLD Promotes TNF-α-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells.Aberrant promoter methylation of hOGG1 may be associated with increased risk of non-small cell lung cancer.CYLD: a deubiquitination enzyme with multiple roles in cancer.DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function.Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines.CYLD regulates keratinocyte differentiation and skin cancer progression in humans.The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines.Epigenetic control of cancer by neuropeptides.Brooke-Spiegler syndrome tumor spectrum beyond the skin: a patient carrying germline R936X CYLD mutation and a somatic CYLD mutation in Brenner tumor.
P2860
Q21136141-87723C90-1347-4B02-BC26-E1EEB5CE3BFBQ24296068-2C7F7DC9-CAAD-4459-BA0E-44626D152E98Q24610335-5B7E7E40-2A0B-4DF3-976C-D9914D4D060DQ24648542-86984A36-D06B-44DC-A61B-6E90305D61F2Q28386334-CBB33D9E-6550-411E-A797-4B6DB2F70EF8Q33321264-CEDA6EF0-259C-4C5A-A979-90F18FA7C4B8Q33523914-94688A4A-2C02-4D79-9DDA-2BF3C96D988DQ33619601-EB2B47D8-5DA4-45BC-90B3-E4F144441207Q33781123-20B5C653-30FA-43F8-A34E-97FBF89EC384Q33785409-D10D4354-6F34-451E-BAB6-BCFD89AE3106Q33947304-2278003B-9047-4DF6-B25F-FAA91ECD3FF3Q34319824-7558624A-EF9D-44F4-9F6E-2068495481CDQ34371189-69FFEAE3-D421-4B0B-BEF2-A54A33ED1DE4Q34505483-B6A3AF89-5049-4F5A-A255-0EAF9ECBB673Q35370365-B337FE05-DA78-4BCD-B02B-6D0E773A7CE2Q35625506-5949D591-F780-4A72-B4B3-A4CB5CE0ADC8Q36152246-335087BB-12C9-49FF-AB89-85A84FD4F132Q36171836-FD7FA16E-C9F3-43F9-9D9A-B522E30EA603Q36178320-A5A57DFC-F05B-4539-87B0-64F32C76F897Q36288148-5869FBC2-81AF-4DF9-8809-F6FC8E9F20ADQ36457427-B92CB395-C1ED-4152-805A-C03B1BA5E386Q36643310-3C5B3AB1-07C2-4F72-9075-8C988C990BEEQ36776566-8093580A-E611-4F7D-B226-3E5E1B784850Q36850367-30A37931-FD2F-4867-B4B7-A77CDFBBC011Q36953248-2AB49864-CB1A-4CAC-B836-4D8E665C0AE8Q36990208-2537F4FD-C92D-46CF-A8D6-16AA2686312DQ37165388-5134B123-6D43-479F-8A41-96382F141570Q37205801-F318C299-630C-4045-A0BE-2EAD4A7D7B33Q37210234-513B3AAE-5798-46FA-BD3F-152DE0E397FDQ37294189-29777BD5-4963-4D85-84AD-BED972DEF815Q37322774-0E9FBE10-C8B7-4730-A4B0-D6A51B8B337CQ37702708-65D8DEED-0353-4FD4-A2EB-F4DB3CF1E65DQ37846231-F610AE2E-CDBC-4B02-AA28-C515C3A662BAQ38296215-E445CD4E-EBC6-4737-AC80-F2DB4DB7AC81Q38493679-A7487611-719C-4B60-BC50-115D332BBF14Q38608670-7C951E01-C284-4D36-8A93-2E7376135789Q38626355-D728771A-C793-4937-A5B7-53C75C22D174Q38749473-6500135B-C017-455B-972A-7AAB65EFECE8Q38998556-9E798337-2CCB-4EC1-9402-D70C358802AAQ39246743-59543A3E-21E0-4513-ABB7-FD330EC44ECA
P2860
Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Pharmacologic inhibition of ep ...... deacetylation in lung cancer.
@en
Pharmacologic inhibition of ep ...... deacetylation in lung cancer.
@nl
type
label
Pharmacologic inhibition of ep ...... deacetylation in lung cancer.
@en
Pharmacologic inhibition of ep ...... deacetylation in lung cancer.
@nl
prefLabel
Pharmacologic inhibition of ep ...... deacetylation in lung cancer.
@en
Pharmacologic inhibition of ep ...... deacetylation in lung cancer.
@nl
P2093
P356
P1433
P1476
Pharmacologic inhibition of ep ...... e deacetylation in lung cancer
@en
P2093
P2888
P304
P356
10.1038/SJ.ONC.1210041
P407
P577
2006-10-09T00:00:00Z